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T Predictors of survival in octogenarians after mitral valve
surgery for degenerative disease: The Mitral Surgery in
Octogenarians studyPierpaolo Chivasso, MD,a Vito D. Bruno, MD, PhD,a Shakil Farid, MBBS, FRCS (C-Th), MBA,b
Pietro Giorgio Malvindi, MD, PhD,c Amit Modi, MBBS, FRCS (C-Th),c Umberto Benedetto, MD, PhD,a
Franco Ciulli, MD,a Yasir Abu-Omar, PhD, FRCS (C-Th),b Massimo Caputo, MD, Mch, FRCS (C-Th),a
Gianni D. Angelini, MD, MCh, FRCS (C-Th), FMedSci,a Steve Livesey, MD, FRCS (C-Th),c and
Hunaid A. Vohra, MD, PhD, FRCS (C-Th)aABSTRACT
Objectives:An increasing number of octogenarians are referred to undergomitral
valve surgery for degenerative disease, and percutaneous approaches are being
increasingly used in this subgroup of patients. We sought to determine the survival
and its predictors after Mitral Valve Surgery in Octogenarians (MiSO) in a multi-
center UK study of high-volume specialized centers.
Methods: Pooled data from 3 centers were collected retrospectively. To identify
the predictors of short-term composite outcome of 30 days mortality, acute kidney
injury, and cerebrovascular accident, a multivariable logistic regression model
was developed. Multiple Cox regression analysis was performed for late mortal-
ity. Kaplan–Meier curves were generated for long-term survival in various subsets
of patients. Receiver operating characteristic analysis was done to determine the
predictive power of the logistic European System for Cardiac Operative Risk
Evaluation.
Results:A total of 247 patients were included in the study. The median follow-up
was 2.9 years (minimum 0, maximum 14 years). A total of 150 patients (60.7%)
underwent mitral valve repair, and 97 patients (39.3%) underwent mitral valve
replacement. Apart from redo cardiac surgery (mitral valve repair 6 [4%] vs
mitral valve replacement 11 [11.3%], P¼ .04) and preoperative atrial fibrillation
(mitral valve repair 79 [52.6%] vs mitral valve replacement 34 [35.1%], P<.01),
there was no significant difference in terms of any other preoperative characteris-
tics between the 2 groups. Patient operative risk, as estimated by logistic European
System for Cardiac Operative Risk Evaluation, was lower in the mitral valve
repair group (10.2  11.8 vs 13.7  15.2 in mitral valve replacement;
P ¼ .07). No difference was found between groups for duration of cardiopulmo-
nary bypass and aortic crossclamp times. The 30-day mortality for the whole
cohort was 13.8% (mitral valve repair 4.7% vs mitral valve replacement
18.6%; P<.01). No differences were found in terms of postoperative cerebrovas-
cular accident (2% vs 3.1%; P¼ .9), acute kidney injury requiring dialysis (6.7%
vs 13.4%; P ¼ .12), and superficial or deep sternal wound infection (10% vs
16.5%, P ¼ .17; 2% vs 3.1%, P ¼ .67, respectively). The final multiple regres-
sion model for short-term composite outcome included previous cardiac surgeryUnited Kingdom; and cUniversity Hospitals Southampton, Wessex Cardiothoracic
Centre, Southampton, United Kingdom.
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In octogenarians, MVr demonstrated good in-
hospital outcomes and provided better survival
compared with MVR.Perspective
An increasing number of octogenarians are un-
dergoing valve surgery, and there is a large
body of evidence showing that octogenarians
derive benefit from cardiac surgery. We demon-
strated that MVr is safe and effective even in
elderly patients, providing better short-term
outcomes and long-term survival compared
with MVR.See Editorial Commentary page 1483.
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Abbreviations and Acronyms
AKI ¼ acute kidney injury
BMI ¼ body mass index
CI ¼ confidence interval
COPD ¼ chronic obstructive pulmonary
disease
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
HR ¼ hazard ratio
IABP ¼ intra-aortic balloon pump
LVEF ¼ left ventricular ejection fraction
MiSO ¼ Mitral Valve Surgery in
Octogenarians
MR ¼ mitral regurgitation
MVr ¼ mitral valve repair
MVR ¼ mitral valve replacement
OR ¼ odds ratio
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you to the supplemental tables
and figure for this article.
(odds ratio [OR], 4.47; 95% confidence interval [CI], 1.37-
17.46; P ¼ .02), intra-aortic balloon pump use (OR, 4.77;
95% CI, 1.67-15.79; P<.01), and mitral valve replacement
(OR, 7.7; 95% CI, 4.04-14.9; P<.01). Overall survival for
the entire cohort at 1, 5, and 10 years was 82.4%, 63.7%,
and 45.5% (mitral valve repair vs mitral valve replacement:
89.9% vs 70.7% at 1 year, 69.6% vs 54% at 5 years, and
51.8% vs 35.5% at 10 years; P ¼ .0005). Cox proportional
hazardmodel results showedmitral valve replacement (haz-
ard ratio, 1.88; 95% CI, 1.22-2.89; P<.01) and intra-aortic
balloon pump use (hazard ratio, 2.54; 95% CI, 1.26-5.13;
P < .01) to be independent predictor factors affecting
long-term survival. Logistic European System for Cardiac
Operative Risk Evaluation did not perform well in
predicting early mortality (area under the curve, 0.57%).
Conclusions: In octogenarians, mitral valve repair for
degenerative disease is associated with good survival
and remains the gold standard, whereas mitral valve replace-
ment is still associated with significant mortality. Logistic
European System for Cardiac Operative Risk Evaluation
was unable to predict earlymortality in our cohort of patients.
Larger international multicenter registries are required to
optimize the decision-making process in such a high-risk
subgroup. (J Thorac Cardiovasc Surg 2018;155:1474-82)
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TIn the past 2 decades, the definition of the ‘‘elderly’’ popu-
lation in the cardiology literature has evolved: initially age
more than 70 years, then more than 75 years, and now more
than 80 years.1,2 The expectancy and quality of life of the
elderly population continue to increase at the cost of a
growing prevalence of cardiovascular conditions,1-4 such
as mitral valve disease. Thus, an increasing number of
octogenarians are referred to undergo cardiac surgical
procedures.4 Mitral valve repair (MVr) is the treatment of
choice for severe mitral regurgitation (MR) in the general
population, because it has been shown to provide a signifi-
cant survival benefit over both medical treatment and mitral
valve replacement (MVR).5-11 However, the feasibility and
efficacy of mitral repair in very elderly patients are more
controversial.12 Overall, there is a large body of evidence
showing that octogenarians derive benefit from cardiac sur-
gery.13-26 In the last decade, several studies have shown that
cardiac surgical procedures performed in elderly patients, in
otherwise good physical and mental health, can improve
their mortality, morbidity, and quality of life.
Transcatheter mitral technologies are emerging as a viable
option to treat high-risk and inoperable patients with mitral
valve disease.27-32 These have shown promising early
outcomes, especially in terms of procedural safety, and
have being increasingly used in otherwise fit octogenarians
requiring intervention for degenerative mitral valve
disease. To this end, a clear understanding of the risks and
benefits of mitral surgery in octogenarians in the current
era is needed for rational decision-making regarding the
best management option in this cohort of patients.
The purpose of this study was to determine the survival
and determinants of its predictors after surgical MVr and
MVR in octogenarians in a multicenter UK study, Mitral
Valve Surgery in Octogenarians (MiSO), of high-volume
specialist centers in the MitraClip (Abbott Vascular, Inc,
Menlo Park, Calif) era.PATIENTS AND METHODS
Study Population and Definitions
MiSO is a multicenter, retrospective, observational study based on pro-
spectively collected data obtained from institutional cardiac surgery data-
sets of 3 high-volume specialist UK centers (Bristol, Papworth, and
Southampton). The study was conducted in accordance with the principles
of the Declaration of Helsinki. Institutional board approval was obtained
for the study, and patient consent was waived.
Between January 2001 and October 2015, 252 octogenarians underwent
mitral valve surgery. All the purely endocarditis, rheumatic, or ischemic
cases were excluded to prevent selection bias. The final cohort consisted
of 247 patients with degenerative MR (Figure E1 shows the distribution
and type of surgery over the years). All patients were approached through
a median sternotomy. Risk scoring has been calculated using the logistic
European System for Cardiac Operative Risk Evaluation (euroSCORE).
Degenerative disease was defined as single- or multi-segment prolapse
due to chordal elongation or rupture. Emergency surgery was defined as
surgery carried out within 24 hours of unscheduled admission, includingdiovascular Surgery c Volume 155, Number 4 1475
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Tpatients presenting with acute decompensation of chronic MR. Patient de-
mographics are summarized in Table 1. Table E1 shows the surgical tech-
niques adopted.
Left ventricular ejection fraction (LVEF) was classified into 3 groups:
good (LVEF 50%), moderate (LVEF>30% and<50%), and poor
(LVEF<30%). Patients were considered to have chronic obstructive pul-
monary disease (COPD) if they had any of the following conditions: long-
term use of bronchodilators or steroids for lung disease before admission;
outpatient visits including a diagnosis of COPD on 2 occasions or a pre-
vious inpatient stay with a discharge diagnosis of COPD; and preopera-
tive lung function test with evidence of obstructive pattern. Patients
were considered to have diabetes if they had any of the following condi-
tions: receipt of insulin or oral hypoglycemic medications before admis-
sion; outpatient visits including a diagnosis of diabetes mellitus on 2
occasions; or a previous inpatient stay with a discharge diagnosis of dia-
betes mellitus.
End Points
The primary end points in the MiSO study were early mortality, defined
as death due to all causes within 30 days from the day of surgery, and long-
term survival. Secondary outcomes included new acute kidney injury
(AKI) requiring dialysis, evidence of postoperative stroke (defined as clin-
ical and radiologic evidence of a new postoperative cerebrovascular event),
return to the operating room for cardiac causes, and sternal wound infection
categorized in superficial (involving the skin, subcutaneous tissue, and pec-
toralis fascia only) and deep (involving sternal bone or mediastinal struc-
tures). Moreover, a composite outcome of death at 30 days or AKI with
dialysis or postoperative cerebrovascular accident was considered for a
multiple logistic regression analysis, designed to identify independent
risk factors affecting early outcomes.TABLE 1. Preoperative characteristics
Characteristic Overall (247)
Age, y 82.8  2.3
Female gender 108 (43.7)
BMI, kg/m2 24.3  3.2
LVEF
Good (50%) 168 (68)
Moderate impairment (30% and<50%) 64 (25.9)
Severe impairment (<30%) 15 (6.1)




Smoking history 113 (45.7)
Previous MI 31 (12.6)
Logistic euroSCORE 11.5  13.4
Previous CVA 19 (7.7)
NYHA III/IV 180 (72.9)
Previous cardiac surgery 17 (6.9)
Emergency 6 (2.4)
Urgency 34 (13.8)
BMI, Body mass index; LVEF, left ventricular ejection fraction; AF, atrial fibrillation; CO
European System for Cardiac Operative Risk Evaluation; CVA, cerebrovascular accident;
1476 The Journal of Thoracic and Cardiovascular SurData regarding long-term survival have been derived from our clin-
ical dataset linked to the Office for National Statistics individually
collected on October 31, 2015. The completeness for survival data
was 100%.
Statistical Analysis
Data are presented as mean 1 standard deviation for numeric contin-
uous variables and as per total number and percentages for categoric vari-
ables. The numeric variables were tested for normality with the Shapiro–
Wilk test. Comparison between numeric variables has been conducted
with the Student t test for normally distributed variables or the Mann–
Whitney U test for not normally distributed variables. Inference on cate-
goric variable has been done using the chi-square or Fisher exact test. To
identify the predictors of composite outcome, a multivariable logistic
regression model was developed: The initial model included those vari-
ables that had a P value less than .25 with univariable analysis (age, pre-
vious cardiac surgery, intra-aortic balloon pump [IABP] use, emergency,
logistic euroSCORE, concomitant coronary artery bypass grafting,
reduced LVEF, and surgical technique): The final model was obtained
by stepwise backward approach selecting for Akaike information criteria.
Survival analysis was conducted using Kaplan–Meier methods and log-
rank test. A Cox proportional hazard model was designed to identify inde-
pendent factors affecting long-term survival. To estimate the predicting
ability of logistic euroSCORE on 30-day mortality, we used receiver oper-
ating characteristics curve analysis. The area under the curve was esti-
mated for observed euroSCORE and the predicted values by fitting
regression model. Missing values were screened before analysis: Every
variable with more than 5% of missing valuewas eliminated from the final
dataset. The remaining variables (Table E2) were imputed using simple
imputation methods. The statistical analysis was conducted with RSurgical technique
Repair (150) Replacement (97) P value
82.9  2.3 82.6  2.5 .12
62 (41.3) 46 (47.4) .41
24.3  3.6 24.4  4.3 .89
.87
102 (68) 66 (68)
38 (25.3) 26 (25.3)
10 (6.7) 5 (6.7)
79 (52.6) 34 (35.1) <.01
8 (5.3) 5 (5.1) 1
80 (53.3) 53 (54.6) .94
16 (10.7) 16 (16.5) .98
71 (47.3) 42 (43.3) .62
17 (11.2) 14 (14.4) .76
10.2  11.8 13.7  15.2 .07
11 (7.3) 8 (8.2) .98
106 (70.6) 74 (76.3) .4
6 (4) 11 (11.3) .04
2 (1.3) 4 (4.1) .21
23 (15.3) 11 (11.3) .37
PD, chronic obstructive pulmonary disease; MI, myocardial infarction; euroSCORE,
NYHA, New York Heart Association.
gery c April 2018
TABLE 2. Operative characteristics and postoperative outcomes
Characteristic
Surgical technique
Overall (247) Repair (150) Replacement (97) P value
CPB time (min) 133.5  52.2 128.9  47.5 140.5  58.3 .21
Crossclamp time (min) 95.9  38 91.1  32.8 103.3  44 .06
Concomitant procedures
CABG 88 (35.6) 55 (36.6) 33 (34) .77
AVR 53 (21.5) 27 (18) 26 (26.8) .14
TV 47 (19) 30 (20) 17 (17.5) .75
AF ablation 19 (7.7) 17 (11.3) 2 (2.1) .02
30-d mortality 25 (13.8) 7 (4.7) 18 (18.6) <.01
CVA 6 (2.4) 3 (2) 3 (3.1) .9
AKI (dialysis) 23 (9.3) 10 (6.7) 13 (13.4) .12
Sternal wound infection 37 (15.2) 18 (12) 19 (20.4) .11
Superficial 31 (12.6) 15 (10) 16 (16.5) .17
Deep 6 (2.4) 3 (2) 3 (3.1) .67
Return to operating room 16 (6.5) 7 (4.7) 9 (9.2) .24
Postoperative length of stay (d) 13.6  11.9 14.1  9.5 12.7  14.7 <.01
Composite outcome (death at 30 d, AKI, CVA) 41 (16.6) 16 (10.6) 25 (25.7) <.01
CPB, Cardiopulmonary bypass; CABG, coronary artery bypass grafting; AVR, aortic valve replacement; TV, tricuspid valve; AF, atrial fibrillation; CVA, cerebrovascular accident;
AKI, acute kidney injury.





Tstatistical software (R version 3.1.2 [2014-10-31] —‘‘Pumpkin Helmet’’;
R Foundation for Statistical Computing, Vienna, Austria).TABLE 3. Multivariable logistic regression model for predictors of
short-term composite outcome (death at 30 days, acute kidney
injury, and cerebrovascular accident)
Predictor OR (95% CI) P value
Previous cardiac surgery 4.47 (1.37-17.46) .02
IABP use 4.77 (1.67-15.79) <.01
Reduced LVEF 1.73 (0.88-3.43) .11
MVR 7.7 (4.04-14.9) <.01
OR, Odds ratio; CI, confidence interval; IABP, intra-aortic balloon pump; LVEF, left
ventricular ejection fraction; MVR, mitral valve replacement.RESULTS
A total of 150 patients (60.7%) underwent MVr, and 97
patients (39.3%) underwent MVR. The median follow-up
was 2.9 years (minimum 0, maximum 14 years); mean
follow-up was 41.4  35.6 months. The distributions of
baseline patient characteristics for the overall population
are presented in Table 1. There were no significant differ-
ences in terms of age, body mass index (BMI), and other
preoperative comorbidities between the 2 groups. The
only significant differences were previous cardiac surgery
(redo) (4% vs 11.3%, P ¼ .04) and preoperative atrial
fibrillation (52.6% vs 35.1%, P< .01) for the MVr and
MVR groups, respectively. The New York Heart
Association class distribution was similar in the 2 groups
(Table 1). Patient operative risk, as estimated by the logistic
euroSCORE, was lower in the MVr group (10.2  11.8 vs
13.7  15.2 in MVR), although this difference was not
statistically significant (P ¼ .07). No difference was found
between groups for duration of cardiopulmonary bypass
and aortic crossclamp times (Table 1). Associated
procedures included 88 coronary artery bypass graftings
(35.6%), 53 aortic valve procedures (21.5%), 47 tricuspid
valve procedures (19%), and 19 (7.7%) atrial fibrillation
ablation procedures. Operative characteristics and
postoperative outcomes are summarized in Table 2. The
30-day mortality for the whole cohort was 13.8% (MVrThe Journal of Thoracic and Car4.7% vs MVR 18.6%; P<.01). No differences were found
in terms of postoperative cerebrovascular accident (MVr
2% vs MVR 3.1%; P ¼ .9) and AKI requiring dialysis
(6.7% vs 13.4%; P¼ .12). The overall incidence of sternal
wound infection was not different between the 2 groups
(12% vs 20.4%; P ¼ .11). The deep sternal wound
infection rate was not different (2% vs 3.1%, P ¼ .67).
The length of stay in hospital after the surgery was found
to be significantly longer in the MVr group
(14.1  9.5 days vs 12.7  14.7 days in MVR; P<.01).
In the subgroup of patients who underwent a redo opera-
tion, the 30-day mortality rate was 16.7% in the repair
group versus 18.2% in the replacement group (P ¼ .9).
The final model logistic regression multivariable analysis
(Table 3) for the short-term composite outcome showed that
previous cardiac surgery (odds ratio [OR], 4.47; 95%diovascular Surgery c Volume 155, Number 4 1477
TABLE 4. Cox proportional hazard ratio multivariable model for
predictor affecting long-term mortality*
Predictor HR (95% CI) P value
BMI 0.94 (0.89-1.01) .09
MVR 1.88 (1.22-2.89) <.01
IABP use 2.54 (1.26-5.13) <.01
Reduced LVEF 1.09 (0.42-2.82) .84
HR, Hazard ratio; CI, confidence interval; BMI, body mass index;MVR, mitral valve
replacement; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection frac-
tion. *Gender has been included as stratum variable.
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(OR, 4.77; 95% CI, 1.67-15.79; P<.01), and MVR (OR,
7.7; 95% CI, 4.04-14.9; P<.01) were independent negative
predictors.
The Cox proportional hazard model results (Table 4)
showed MVR (hazard ratio [HR], 2.16; 95% CI, 1.42-3.3;
P < .01) and IABP use (HR, 2.67; 95% CI, 1.52-4.7;
P < .01) to be independent predictor factors affecting
long-term survival. BMI was found to be a protective factor
(HR, 0.95; 95% CI, 0.89-1.00; P ¼ .06).
Overall survival for the entire cohort at 1, 5, and 10 years
was 82.4% (95% CI, 77.8-87.3), 63.7% (95% CI, 57.0-
71.2), and 45.5% (95% CI, 36.0-57.5): MVr versus
MVR: 89.9% (95% CI, 85.2-94.9) versus 70.7% (95%
CI, 62.1-80.5) at 1 year, 69.6% (95% CI, 61.2-79.1) versus
54.0% (95% CI, 43.5-67.1) at 5 years, and 51.8% (95%
CI, 39.4-68.2) versus 35.5% (95% CI, 22.9-55.1) at
10 years, respectively (P<.01) (Figures 1 and 2). Logistic
euroSCORE was unable to predict early and late mortality
(area under the curve, 50.7%) (Figures 3 and 4).FIGURE 1. Kaplan–Meier survival curv
1478 The Journal of Thoracic and Cardiovascular SurDISCUSSION
In the MiSO study, we found that in octogenarians, MVr
for degenerative disease is associated with good early out-
comes and late survival. MVR is still associated with signif-
icant mortality. Furthermore, previous cardiac surgery and
the use of perioperative IABP are associated with decreased
long-term survival, and increased BMI seems to be protec-
tive. Logistic euroSCORE does not seem to effectively pre-
dict early outcome in this group of patients.
The last 2 decades have seen a growing proportion of
octogenarian patients being referred for mitral valve sur-
gery.1-4 This increasing demand is related to prolonged
life expectancy and reported better outcome of mitral
surgery in this population.3-11 However, approximately
half of patients affected by severe MR are not referred for
surgery mainly because of their advanced age,
comorbidities, and left ventricular dysfunction,2,4 and in
specialized centers there seems to be an increasing trend
to treat elderly patients with percutaneous procedures.27,28
This reflects the misperception that mitral valve surgery is
associated with prohibitively high early mortality in this
age group. The decision for surgery is complex; several
elements, such as the lack of correspondence between
physiologic and chronologic age, the quality of life, and
the risk–benefit ratio, should be taken into account before
confirming a surgical indication. This article, analyzing
the early and long-term outcomes of 247 octogenarians un-
dergoing conventional mitral valve surgery, is aimed at as-
sisting in making an informed decision for the patients and
the clinicians regarding surgery or catheter-based mitral
intervention in octogenarian patients with degenerative
mitral valve disease.e for the overall surgical population.
gery c April 2018
FIGURE 2. Kaplan–Meier survival curves between the 2 groups (raw data).





TThe results of our study suggest that being octogenarians
does not necessarily implicate higher surgical risk. With the
help of receiver operating characteristics analysis, we have
confirmed the suspicion that the logistic euroSCORE does
not provide a valid means of determining the predicted mor-
tality in this unique subset of patients, and there is a need to
generate a mitral score on the basis of large multicenter
mitral valve surgery registries, especially for very high-
risk patients.
In our study, 30-day mortality for the whole cohort was
13.8% (MVr 4.7% vs MVR 18.6%; P<.01). This result
is similar to reports by other series; the operative mortality
in a cohort of 2700 octogenarian patients undergoing MVRFIGURE 3. Impact of euroSCORE on survival: Kaplan–Meier survival curve
The Journal of Thoracic and Carbetween 1997 and 2000 from the Society of Thoracic Sur-
geons National Cardiac Database was 16.9%.13 In smaller
single-center studies, operative mortality has ranged from
15% to 20%,13,14,17,19,20,22 which is similar to what we
observed in our overall cohort. However, lower operative
mortality has been reported in elderly patients with
nonischemic MR undergoing isolated mitral surgery
similar to that reported in this article. Moreover, with an
overall survival of 63.7% at 5 years and 45.5 at 10 years,
we showed that this surgery has important long-term bene-
fits even in octogenarians, with a substantial superiority of
MVr compared with MVR. It has been shown that MVr is
preferred over MVR to treat MR due to degenerative mitrals. euroSCORE, European System for Cardiac Operative Risk Evaluation.
diovascular Surgery c Volume 155, Number 4 1479
FIGURE 4. Predictive value of euroSCORE (receiver operating characteristics [ROC] curve). AUC, Area under the curve.
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vivals.5-11 Initially, MVr was considered to be an
unnecessary procedure in elderly subjects; moreover,
there were concerns that fragile tissues and valvular
calcification were more likely to preclude satisfactory
valve repair in older patients.14 However, with increasing
skill and understanding of mitral disease, the repair rate,
especially in expert hands in high-volume centers, has
continued to grow in the last few years.12-26 Our study
confirms this trend, with an increasing ratio of MVr to
MVR over time in octogenarians without significant
cardiopulmonary bypass time difference between the 2
techniques. In the octogenarian population, a survival of
approximately 70% at 5 years and approximately 52% at
10 years after MVr for degenerative MR in our high-
volume multicenter experience strengthens the case to
recommend MVr as the gold standard for degenerative
MR in octogenarians.1480 The Journal of Thoracic and Cardiovascular SurAn increasingly emerging alternative in treating mitral
valve disease is represented by the minimally invasive
approach through right minithoracotomy. Faster recovery
and reduced pain make this approach a valid and reliable
substitute to classic median sternotomy.33-38 There is a
large body of evidence in the literature showing that
minimally invasive mitral valve surgery is not inferior to
the conventional surgical approach using a full
sternotomy, especially with regard to operative results and
long-term survival.34,35 This seems to be valid even in
octogenarians, with some authors reporting a trend toward
a lower operative mortality, rate of transfusion, and an
overall faster recovery with shorter postoperative hospital
stays for the minimally invasive approach.36-38
Transcatheter mitral technologies have developed as a
viable option to treat high-risk and inoperable patients
with severe MR, having shown promising early outcomes,
especially in terms of procedural safety.27-32 Buzzatti andgery c April 2018





Tcolleagues30 recently published their results comparing the
outcomes of patients aged 80 years or more, affected by iso-
lated degenerative MR, who underwent isolated transcath-
eter (n ¼ 25) or surgical (n ¼ 35, 29 repairs and 6
replacements) mitral intervention. Follow-up overall mor-
tality was higher in the MitraClip group (MitraClip System,
Abbott Vascular, Inc) than in the surgery group, although af-
ter the first 30 days, only 1 of 5 deaths observed in the Mi-
traClip group was cardiac related. Regardless of survival, as
confirmed by Lim and colleagues31 in a population of pa-
tients with prohibitive-risk degenerative MV, the MitraClip
can make octogenarians with severe degenerative MR feel
better, reducing their symptoms and improving their quality
of life. A recent meta-analysis by Takagi and colleagues32
comparing the MitraClip with surgical repair for MR in
all age groups showed similar early and late mortality sur-
vival between the 2 procedures, despite higher-risk profiles
in the percutaneous intervention group.
An interesting finding of this study is represented by the
protective effect of BMI. There is increasing evidence
regarding the protective role of obesity in cardiac sur-
gery.39,40 In an apparent paradox, morbidity and mortality
are lower in obese patients undergoing cardiac surgery,
although the nature of this association is unclear. Even in
our subgroup of octogenarians undergoing mitral valve
surgery, this protective effect was confirmed.Study Limitations
This study is retrospective and multicenter, and thus has
the associated limitations of potential heterogeneity. It in-
cludes a small cohort of patients, and because of the logis-
tics, it was not possible to achieve long-term clinical
echocardiographic follow-up for all the 3 centers. Moreover
it lacks data on the indication for repair or replacement at
the time of surgery and therefore is unable to correctly
delineate factors affecting surgical selection, and also
does not provide information on the long-term cause of
death. The absence of a nonsurgical group (ie, medical
treatment or transcatheter treatment) is another important
limitation.CONCLUSIONS
In the MiSO study involving high-volume mitral
specialist centers, we have demonstrated that in octogenar-
ians, MVr for degenerative disease is associated with very
good survival and should be considered the gold standard.
Predictors of poor long-term survival include previous car-
diac surgery and the need for perioperative IABP. Larger in-
ternational multicenter registries are required to create a
powerful scoring system in guiding decision-making in
such a high-risk subgroup because the logistic euroSCORE
does not accurately reflect the exact risk profile of these
patients.The Journal of Thoracic and CarConflict of Interest Statement
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FIGURE E1. Distribution and type of mitral valve surgeries over the years. MV, Mitral valve.
TABLE E1. Surgical characteristics
Characteristic
Surgical technique
Repair (150) Replacement (97)
Repair type*
Leaflet resection 43 (37.1) NA
Annuloplasty ring 116 (100) NA
Neochordae 43 (37.1) NA
Replacement
Mechanical NA 10 (10.3)
Biological NA 87 (89.7)
Prostheses size
23 mm NA 2
25 mm NA 16
27 mm NA 20
29 mm NA 26
31 mm NA 18
33 mm NA 15
Procedures per center
Center A 58 23
Center B 40 35
Center C 52 39
NA, Not available. *Data available for 116 patients (77.3% of the total).
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Age, y 0 0
Female gender 0 0
BMI, kg/m2 0 0
LVEF 3 1.2




Smoking history 1 0.4
Previous MI 2 0.8
Logistic euroSCORE 5 2
Previous CVA 2 0.8
NYHA III/IV 0 0
Previous cardiac surgery 1 0.4
Operative urgency 0 0
CPB time 2 0.8
Crossclamp time 2 0.8
Concomitant procedures 1 0.8
30-d mortality 0 0
CVA 4 1.6
AKI (dialysis) 2 0.8
Sternal wound infection 0 0
Return to operating room 0 0
Postoperative length of stay (d) 0 0
BMI, Body mass index; LVEF, left ventricular ejection fraction; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction; euroSCORE, European
System for Cardiac Operative Risk Evaluation; CVA, cerebrovascular accident;
NYHA, New York Heart Association; CPB, cardiopulmonary bypass; AKI, acute kid-
ney injury.
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